Pre-made Rilotumumab benchmark antibody ( Whole mAb, anti-HGF therapeutic antibody, Anti-DFNB39/F-TCF/HPTA/SF Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-483
Pre-Made Rilotumumab biosimilar, Whole mAb, Anti-HGF Antibody: Anti-DFNB39/F-TCF/HPTA/SF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Rilotumumab biosimilar, Whole mAb, Anti-HGF Antibody: Anti-DFNB39/F-TCF/HPTA/SF therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Colorectal cancer;Gastric cancer;Glioma;Prostate cancer;Renal cancer;Small cell lung cancer;Solid tumours|
|Development Tech||Abgenix XenoMouse|